Author(s): Michael Cohan

Innovator drug sourcing challenges

Contents Editor’s Letter What to look forward to in GaBI Journal, 2018, Issue 2 Commentary Potential changes to the FDA approach to biosimilars have a global impact Original Research Patient-reported outcome measures in phase III trials of LY2963016 insulin glargine and reference insulin glargine products: ELEMENT 1 and ELEMENT 2 Review Article Protein heterogeneity and…

Contents Editor’s Letter Editor’s introduction to the initial issue of the eighth volume of GaBI Journal Legal Biosimilars: considerations in light of the Italian legal framework Special Report Patent expiry dates for biologicals: 2018 update Pharma News Top developments in biosimilars during 2018 Abstracted Scientific Content Regulatory requirements for the acceptance of foreign comparator products…

Contents Editor's Letter Editor’s introduction to the wide range of topics in the initial issue of the second volume of GaBI Journal Letters to the Editor The ethics of biosimilars Austria increases dialogue in order to involve physicians more with biosimilars Editorial Health authority perspective on biosimilars Commentary The case for biosimilars–a payer’s perspective Original…

Author(s): Jennifer Campbell

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2017. Professor Daan JA Crommelin, The Netherlands Dr Alessandro Curto, Italy Professor Francisco Jose de Abajo Iglesias, Spain Professor Theodor Dingermann, Germany…

Contents Editor’s Letter What to look forward to in GaBI Journal, 2021, Issue 2 Original Research Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching Variation in the prices of oncology medicines across Europe and the implications for the future Review…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2012. Ms Arpah Abas, Malaysia Dr Ibrahim Alshwaier, Saudi Arabia Professor Saleh Alsuwayeh, Saudi Arabia Dr Christoph Baumgärtel, Austria Professor Daniel Benjamin, USA…

Contents Editor's Letter What to look forward to in GaBI Journal, 2013, Issue 2 Editorial National and regional activities by sickness funds in Austria to encourage the rational use of medicines Letters to the Editor Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx Challenges to generic medicines utilization in Yemeni healthcare system Original Research…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2013. Dr Ibrahim Aljuffali, Saudi Arabia Professor Saleh Alsuwayeh, Saudi Arabia Professor Alain Astier, France Dr Christoph Baumgärtel, Austria Professor Mohamed Izham Bin…

Contents Editor's Letter Latest features in GaBI Journal, 2013, Issue 3 Editorial Italy’s final position paper on biosimilars and new price and reimbursement pathway Commentary Commentary on the recommendations of the European Society for Organ Transplantation Advisory Committee on generic substitution of immunosuppressive drugs Biosimilar monoclonal antibodies—challenges and opportunities in Europe Ongoing initiatives in the…

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI Journal) in 2014. Ms Arpah Abas, Malaysia Dr Christoph Baumgärtel, Austria Professor Daniel Kelly Benjamin Jr, USA Professor Gerrit Borchard, Switzerland Dr Chiann Chang, Brazil…